Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCA versus intralesional Glucantime for lupoid cutaneous leishmaniasis
IRCT201101313862N6Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Nov 2009
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of trichloroacetic acid and meglumine antimoniate in cutaneous leishmaniasis (CL) (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoint: Improvement of lesions. Started Nov 2009; status: completed.
02
Drugs
trichloroacetic acidmeglumine antimoniate
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on IRCT201101313862N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201101313862N6.